No treatment available today can eliminate HSV-1 from your body. The virus permanently embeds its DNA in nerve cells, entering a dormant state that survives every antiviral drug on the market. What you can do is suppress outbreaks, reduce how often the virus reactivates, lower the chance of spreading it, and wait for genuinely curative therapies that are now in active development. The gap between “manageable” and “curable” is real, but it is narrowing faster than most people realize.
Why the Virus Stays for Life
After an initial infection, HSV-1 travels along sensory nerves and settles into clusters of nerve cell bodies called ganglia, most commonly the trigeminal ganglia near the base of the skull. Once inside those neurons, the virus essentially powers down. It stops replicating, stops making the proteins that would flag the cell for destruction by the immune system, and instead produces just one major gene product: a non-coding RNA called the latency-associated transcript, or LAT. Research in mouse models shows that LAT actively represses the virus’s own genes, keeping them quiet, and that viruses lacking LAT reactivate more frequently than those that have it.
Your immune system knows the virus is there. Studies of trigeminal ganglia removed from otherwise healthy people found CD8-positive T cells and macrophages clustered specifically around neurons harboring latent HSV-1, while uninfected ganglia showed no such immune presence. Those T cells produce interferon-gamma and other signaling molecules that help keep the virus in check without killing the neurons it lives in. It is a standoff: the virus hides well enough to avoid destruction, and the immune system patrols closely enough to prevent constant reactivation. Neither side wins outright.
What Antiviral Drugs Actually Do
Acyclovir and its relatives, valacyclovir and famciclovir, remain the only approved medicines for HSV infections. They work by blocking the virus’s ability to copy its DNA during active replication. That makes them effective at shortening outbreaks and reducing how much virus you shed, but they have a fundamental limitation: they do nothing to the dormant virus sitting silently in your nerve cells. As one review put it, the virus “cannot be completely eradicated because HSV viruses are able to change into their latent form which can survive the treatment.”
For most people, antiviral resistance is not a practical concern. A study of patients in southern Taiwan found that fewer than 2% of those with weakened immune systems harbored acyclovir-resistant HSV-1. A separate analysis of patients with blood cancers found a much higher rate of resistance in lab testing, around 69% of isolates, but this did not translate into worse treatment outcomes: patients with resistant strains responded to therapy at the same rate and in the same time frame as those with sensitive strains. The disconnect between lab resistance and real-world failure suggests that the immune system, even when compromised, still does much of the heavy lifting during treatment.
Daily suppressive therapy with valacyclovir is the standard approach for people who want to reduce outbreak frequency and lower the risk of transmitting the virus. It does not eliminate shedding entirely, but it cuts it substantially. For cold sores specifically, the usual approach is episodic treatment: you start the medication at the first tingle and take it for a few days. Neither approach touches the latent reservoir.
Over-the-Counter and Supplement Options
Docosanol, sold as Abreva in the United States, is the one non-prescription topical with solid clinical trial data behind it. In a multicenter trial of over 700 patients, those using docosanol cream healed about 18 hours faster than those using a placebo, with quicker resolution of pain, itching, and tingling. That is a modest benefit, but it is real and statistically significant. The catch is that docosanol only works if applied early, ideally at the first sign of a prodrome.
L-lysine, an amino acid available as an inexpensive supplement, has a long folk reputation for preventing cold sores. A narrative review concluded that daily lysine supplementation can reduce the frequency of recurrences and shorten healing time during outbreaks. The evidence is not as rigorous as what exists for prescription antivirals, and doses used in studies vary, but many clinicians consider it a reasonable low-risk addition to a management plan. Lysine is thought to work by interfering with the virus’s use of arginine, another amino acid it needs for replication, though the mechanism is not fully nailed down.
Gene Editing and the Possibility of a Cure
The most exciting development in HSV research is the use of gene editing to physically destroy viral DNA hiding inside neurons. A team led by researchers at the Fred Hutchinson Cancer Center has developed an approach using engineered meganucleases, which are proteins that cut DNA at very specific sequences, delivered into nerve cells by harmless viral vectors called AAVs. In mouse models of orofacial infection, a combination of two anti-HSV-1 meganucleases delivered by multiple AAV types eliminated 90% or more of latent viral DNA. In models of genital infection the figure reached 97%.
Getting the editing tools into the right cells is one of the biggest engineering challenges. The virus hides in neurons whose cell bodies sit deep inside ganglia, but their nerve endings extend out to the skin and mucous membranes. Researchers have shown that AAV vectors injected into peripheral tissue, like skin or the corneal surface, can travel backward along these nerves to reach the ganglia. AAV serotype 1 appears particularly efficient at this retrograde delivery to trigeminal ganglia neurons, with gene expression increasing steadily over the first month after injection.
CRISPR/Cas9, the more widely known gene-editing system, has also been tested against herpesviruses in laboratory settings. It can target and disrupt the viral genome during latency, and researchers have applied it to HSV, Epstein-Barr virus, cytomegalovirus, and other members of the herpesvirus family. CRISPR-based approaches for HSV are further from the clinic than the meganuclease strategy, but they represent a second independent path toward a functional cure.
Neither approach is available to patients yet. The meganuclease therapy is the most advanced, with preclinical results strong enough to attract significant funding and move toward human trials. The gap between “works in mice” and “safe and effective in humans” is real, but the results so far are unlike anything the field has seen before. For the first time, researchers can credibly talk about eliminating latent HSV rather than just suppressing it.
New Drug Classes Beyond Acyclovir
Helicase-primase inhibitors represent the first genuinely new mechanism of action for anti-herpes drugs in decades. Unlike acyclovir, which blocks viral DNA copying after a chain has started, these drugs prevent the viral DNA from being unwound and primed for replication in the first place. Pritelivir, the furthest along, has been tested in both animal models and human trials. In a mouse model of HSV-1 infection, pritelivir at a standard dose completely suppressed all signs of infection over a four-day treatment course. In a human trial focused on genital HSV-2, the drug reduced viral shedding in a dose-dependent way, with the highest daily dose cutting shedding days to about one-eighth of the placebo rate and reducing days with visible lesions by a similar margin. A second-generation helicase-primase inhibitor, ABI-5366, is currently in Phase I clinical trials. These drugs are not cures either, but they offer a meaningful alternative for patients who do not respond well to acyclovir or who develop resistance.
Monoclonal antibodies are another emerging approach. HDIT101 is a humanized antibody that targets glycoprotein B, a protein found on the surface of both HSV-1 and HSV-2 particles and on the surface of infected cells. It has completed a first-in-human safety trial in healthy volunteers. A companion antibody, HDIT102, targets a different spot on the same protein, and the combination of the two showed synergistic effects in mice: better survival and clinical outcomes than either antibody alone. The antibodies work by neutralizing free virus, blocking the virus from spreading directly between cells, and flagging infected cells for destruction by the immune system. This class of therapy is most likely to find its niche in severe or neonatal infections, where rapid viral control matters more than long-term suppression.
Therapeutic Vaccines
A preventive HSV vaccine, one that stops you from getting infected in the first place, does not exist. Therapeutic vaccines, which aim to boost the immune response in people already infected and thereby reduce outbreaks and shedding, have been pursued for decades with limited success. A comprehensive review of clinical trials describes a long list of approaches that failed to show enough benefit to move forward, including inactivated virus, extracted viral proteins, recombinant glycoproteins, and live-attenuated strains.
A few candidates have shown partial efficacy. A DNA vaccine expressing two viral proteins reduced new genital lesions by 57% compared with placebo but did not reduce shedding. One of the more promising candidates, developed by Genocea, combined a piece of the viral protein ICP4 with glycoprotein D and an adjuvant. It reduced lesion rates by roughly 37% to 51% compared with placebo and shortened the duration of recurrences by just over a day. But the developers themselves questioned whether a vaccine that reduces disease by about half for about a year could compete with daily antivirals that are more effective. The vaccine was not studied further.
Newer platforms may change the calculus. An mRNA vaccine tested in mice produced complete protection against lethal HSV-1 and HSV-2 challenge, with no detectable viral DNA in the dorsal root ganglia of vaccinated animals four weeks after infection. mRNA technology allows rapid iteration and strong immune responses, and the success of mRNA COVID vaccines has attracted investment to the platform. Whether these preclinical results translate to humans remains to be seen, but the platform’s flexibility makes it one of the more plausible routes to a working HSV vaccine.
What Triggers Reactivation
Understanding reactivation triggers matters because reducing how often the virus wakes up is, for now, the most practical way to manage HSV-1. The virus can be jolted out of latency by a variety of stimuli, and research has identified both common and distinct mechanisms behind different triggers.
Psychological and physiological stress is one of the best-documented triggers. Stress hormones activate the glucocorticoid receptor, which directly stimulates viral promoters that drive expression of key reactivation proteins. In animal models, a corticosteroid-blocking drug impaired both viral replication and reactivation. UV light is another well-established trigger: studies in mice show that UV-B exposure to the eye reactivates HSV-1 in the corneas of virtually all latently infected animals. Fever, illness, menstruation, dental procedures, and local tissue trauma are also commonly reported triggers, though the strength of evidence varies.
The role of CD8-positive T cells in preventing reactivation is critical. These immune cells use non-destructive mechanisms to keep the virus quiet in neurons. When this T-cell response is disrupted, whether by immunosuppressive drugs, HIV, or other conditions, reactivation becomes more frequent and can cause more severe disease. A case report of a patient with rheumatoid arthritis on the immunosuppressive drug methotrexate illustrates the point: the patient developed severe herpes-related corneal inflammation, and adjusting the immunosuppressive regimen was key to controlling the infection.
Asymptomatic Shedding
One of the most frustrating aspects of HSV-1 is that you can transmit it even when you have no symptoms. Oral shedding of HSV-1 is surprisingly common. When researchers used PCR testing, which is more sensitive than older culture methods, they found HSV-1 DNA in the mouths of about 54% of seropositive individuals across multiple visits, with virus detectable on roughly a third of all days tested. Shedding episodes typically lasted one to three days, though about 10% of patients shed for longer. The rate varied enormously between people, from zero to 92% of days tested.
This variability matters for transmission risk. Some people shed frequently and are much more likely to pass the virus to partners, children, or others through casual contact like kissing. Others shed rarely. There is currently no practical way to predict where you fall on that spectrum, though higher antibody levels and more frequent outbreaks are rough indicators of a more active viral reservoir. Suppressive antiviral therapy reduces but does not eliminate asymptomatic shedding.
Diagnostic Pitfalls
If you have ever tried to get tested for HSV-1, you may have run into the limitations of current testing. The standard blood test detects antibodies, not the virus itself, and its accuracy is far from perfect. A study comparing antibody tests against PCR, the gold standard for confirming active infection, found that HSV-1 IgG antibody testing had an accuracy of only about 64% for detecting HSV-1 infection. When both HSV-1 and HSV-2 antibodies were positive, the combined accuracy for identifying which virus was actually present dropped to around 35%.
False negatives are common early in infection, before the body has produced enough antibodies to detect. False positives occur because of cross-reactivity between HSV-1 and HSV-2 antibodies. For someone with a history of cold sores, the clinical picture is usually clear enough that testing adds little. For someone without obvious symptoms who wants to know their status, a positive antibody test is suggestive but not definitive, and a negative test does not rule out infection with certainty, especially if exposure was recent. PCR swab testing during an active outbreak is far more reliable for confirming diagnosis.
HSV-1 and Alzheimer’s Disease
A growing body of research links HSV-1 to Alzheimer’s disease, though the relationship is complex and not fully established. Viral proteins have been detected in brain regions affected by Alzheimer’s, and researchers have proposed that repeated reactivation of the virus in the brain drives chronic neuroinflammation, promotes the accumulation of amyloid-beta plaques and tau tangles, and damages synapses. One analysis from a large prevention trial found that participants with HSV-1 infection and the APOE4 genetic risk factor for Alzheimer’s had a different pattern of brain amyloid accumulation than uninfected participants, with the association being strongest in APOE4 carriers.
The practical takeaway is uncertain. Some researchers have suggested that antiviral therapy could reduce Alzheimer’s risk in HSV-1 carriers, and observational studies from Taiwan have hinted at this, but no randomized trial has tested the idea. The link between HSV-1 and neurodegeneration is one more reason researchers are pursuing curative gene-editing strategies: if the virus contributes to brain disease over a lifetime of periodic reactivation, eliminating the latent reservoir could have benefits beyond preventing cold sores.
An Ancient Evolutionary Partnership
HSV-1 is not a recent invader. Phylogenetic analysis suggests that it has been coevolving with human ancestors through a process of codivergence stretching back millions of years, tracking the branching of primate species. HSV-2, by contrast, appears to have jumped into the human lineage from the ancestor of modern chimpanzees roughly 1.6 million years ago. HSV-1 has been with us so long that its genetic variation across human populations has been used as a tool to trace ancient human migration patterns and population splits, much like mitochondrial DNA.
This deep evolutionary history helps explain why the virus is so extraordinarily good at what it does. Millions of years of coevolution have equipped HSV-1 with a sophisticated toolkit for evading immune detection, establishing latency in exactly the right cell type, and reactivating just often enough to spread to new hosts without killing the current one. It also means that any therapeutic strategy aiming to outsmart the virus is working against a formidably well-adapted opponent, which is part of why the gene-editing approach, which physically destroys the viral DNA rather than trying to outmaneuver the virus’s evolved defenses, holds particular promise.